Patents by Inventor Gryssell Rodriguez Martinez

Gryssell Rodriguez Martinez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for making a homogenous vaccine composition comprising a conjugate of EGF and 64K for the treatment of tumors
    Patent number: 8841251
    Abstract: A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: September 23, 2014
    Assignee: Centro de Immunologia Molecular (CIM)
    Inventors: Gryssell Rodriguez Martinez, Lisel Vina Rodriguez, Loany Calvo Gonzalez, Ariadna Cuevas Fiallo, Ernesto Chico Veliz, Agustin Bienvenido Lage Davila, Tania Crombet Ramos, Arama Albisa Novo, Gisela Maria Gonzalez Marinello
  • Homogenous Vaccine Composition Comprising a Conjugate of EGF and P64K for the Treatment of Tumors
    Publication number: 20130039940
    Abstract: A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.
    Type: Application
    Filed: January 10, 2012
    Publication date: February 14, 2013
    Inventors: Gryssell Rodriguez Martinez, Lisel Vina Rodriguez, Loany Calvo Gonzalez, Ariadna Cuevas Fiallo, Ernesto Chico Veliz, Agustin Bienvenido Lage Davila, Tania Crombet Ramos, Arama Albisa Novo, Gisela Maria Gonzalez Marinello